USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AURASENSE THERAPEUTICS, LLC
Address:
8045 Lamon Ave
SUITE 410
SKOKIE, IL 60077-5317
EIN:
145263844
DUNS:
968721535
Number of Employees:
16
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $374,230.00 2
SBIR Phase II $986,621.00 1
STTR Phase I $149,941.00 1

Award List:

Genetically Programmable Spherical Nucleic Acids as Rapidly Adaptable Nanotherapeutics

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$149,295.00
Agency / Branch:
DOD / DARPA
Principal Investigator:
David Giljohann, Chief Scientific Officer – (847) 467-2887
Abstract:
AuraSense Therapeutics is developing oligonucleotide-modified gold nanoparticles called spherical nucleic acid (SNA) constructs, which are a powerful new way of regulating cellular gene expression. AuraSense Therapeutics will use SNAs as genetically programmable antimicrobial agents in a manner to… More

Genetically Programmable Spherical Nucleic Acids as Rapidly Adaptable Nanotherapeutics

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$986,621.00
Agency / Branch:
DOD / DARPA
Principal Investigator:
David Giljohann, COO – (847) 673-1702
Abstract:
AuraSense Therapeutics is developing oligonucleotide-modified gold nanoparticles called Spherical Nucleic Acid (SNA) constructs, which are a powerful new way of regulating cellular gene expression. AuraSense Therapeutics will use SNAs as genetically programmable antimicrobial agents in a manner to… More

Topically-delivered Mutation-specific Gene Targeting for Epidermolytic Ichthyosis

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$224,935.00
Agency:
HHS
Principal Investigator:
David A. Giljohann – 847-673-1702
Abstract:
DESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized… More

Topically-delivered Targeted Gene Suppression of Immune Activation in Psoriasis

Award Year / Program / Phase:
2014 / STTR / Phase I
Award Amount:
$149,941.00
Agency:
HHS
Principal Investigator:
David A. Giljohann – 847-673-1702
Research Institution:
NORTHWESTERN UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized… More